Total Payments
$15,362
2024 Payments
$3.49
Companies
8
Transactions
11
Medicare Patients
17,741
Medicare Billing
$7.5M
Payment Breakdown by Category
Research$15,211 (99.0%)
Food & Beverage$114.77 (0.7%)
Education$35.81 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $15,211 | 3 | 99.0% |
| Food and Beverage | $114.77 | 5 | 0.7% |
| Education | $35.81 | 3 | 0.2% |
Payments by Type
Research
$15,211
3 transactions
General
$150.58
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $15,211 | 3 | $0 (2022) |
| Tactile Systems Technology Inc | $72.90 | 2 | $0 (2022) |
| PUMA BIOTECHNOLOGY, INC. | $23.27 | 1 | $0 (2022) |
| Amgen Inc. | $15.11 | 1 | $0 (2023) |
| Seattle Genetics, Inc. | $12.29 | 1 | $0 (2018) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
| Exelixis Inc. | $11.60 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3.49 | 1 | PFIZER INC. ($3.49) |
| 2023 | $15.11 | 1 | Amgen Inc. ($15.11) |
| 2022 | $15,250 | 5 | Eli Lilly and Company ($15,154) |
| 2021 | $69.32 | 2 | Eli Lilly and Company ($57.40) |
| 2020 | $11.60 | 1 | Exelixis Inc. ($11.60) |
| 2018 | $12.29 | 1 | Seattle Genetics, Inc. ($12.29) |
All Payment Transactions
11 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/29/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $3.49 | General |
| Category: ONCOLOGY | ||||||
| 05/11/2023 | Amgen Inc. | LUMAKRAS (Drug) | Food and Beverage | In-kind items and services | $15.11 | General |
| Category: Oncology | ||||||
| 12/08/2022 | Tactile Systems Technology Inc | Flexitouch Plus (Device), entre | Food and Beverage | In-kind items and services | $56.17 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 11/15/2022 | Eli Lilly and Company | — | — | In-kind items and services | $22.00 | Research |
| Study: EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | ||||||
| 11/10/2022 | Tactile Systems Technology Inc | Flexitouch Plus (Device), entre | Food and Beverage | In-kind items and services | $16.73 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 08/30/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $15,132.00 | Research |
| Study: EMBER-3: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF LY3484356 VS INVESTIGATOR'S CHOICE OF ENDOCRINE THERAPY, IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ENDOCRINE THERAPY | ||||||
| 05/04/2022 | PUMA BIOTECHNOLOGY, INC. | NERLYNX (Drug) | Food and Beverage | In-kind items and services | $23.27 | General |
| Category: ONCOLOGY | ||||||
| 09/14/2021 | Eli Lilly and Company | — | — | In-kind items and services | $57.40 | Research |
| Study: EMBER-3: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF LY3484356 VS INVESTIGATOR'S CHOICE OF ENDOCRINE THERAPY, IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ENDOCRINE THERAPY | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 02/26/2020 | Exelixis Inc. | Cabometyx (Drug) | Education | In-kind items and services | $11.60 | General |
| Category: Oncology | ||||||
| 04/11/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EMBER-3: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF LY3484356 VS INVESTIGATOR'S CHOICE OF ENDOCRINE THERAPY, IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ENDOCRINE THERAPY | Eli Lilly and Company | $15,189 | 2 |
| EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | Eli Lilly and Company | $22.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 85 | 4,781 | 142,678 | $10.3M | $1.9M |
| 2022 | 74 | 4,363 | 149,424 | $8.6M | $1.8M |
| 2021 | 74 | 4,089 | 137,388 | $8.4M | $2.0M |
| 2020 | 84 | 4,508 | 173,325 | $8.9M | $1.8M |
Total Patients
17,741
Total Services
602,815
Medicare Billing
$7.5M
Procedure Codes
317
All Medicare Procedures & Services
317 procedure records from CMS Medicare Utilization — Page 1 of 13
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 33 | 18,900 | $2.8M | $817,063 | 29.5% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 13 | 14,020 | $1.1M | $332,120 | 29.0% |
| J1930 | Injection, lanreotide, 1 mg | Office | 2023 | 12 | 2,280 | $554,040 | $99,618 | 18.0% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 16 | 3,400 | $659,600 | $77,276 | 11.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 306 | 656 | $176,674 | $60,540 | 34.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 17 | 3,120 | $220,920 | $57,858 | 26.2% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 12 | 1,676 | $416,952 | $55,815 | 13.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 164 | 529 | $441,435 | $52,940 | 12.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 109 | 254 | $92,276 | $33,492 | 36.3% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 22 | 12,230 | $256,830 | $28,804 | 11.2% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 16 | 360 | $519,840 | $28,243 | 5.4% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 27 | 27,750 | $138,750 | $24,333 | 17.5% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 50 | 15,860 | $142,740 | $21,832 | 15.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 216 | 241 | $43,705 | $14,700 | 33.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 354 | 1,637 | $57,295 | $12,424 | 21.7% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 37 | 168 | $11,760 | $11,966 | 101.8% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 295 | 1,146 | $71,052 | $11,834 | 16.7% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 18 | 56 | $55,216 | $10,315 | 18.7% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 18 | 75 | $295,350 | $10,061 | 3.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 128 | 741 | $77,805 | $8,711 | 11.2% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 61 | 171 | $69,618 | $8,587 | 12.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 90 | 155 | $47,120 | $7,538 | 16.0% |
| J9041 | Injection, bortezomib, 0.1 mg | Office | 2023 | 12 | 1,995 | $247,380 | $6,927 | 2.8% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 24 | 118 | $29,401 | $6,444 | 21.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 288 | 705 | $13,395 | $5,906 | 44.1% |
About Dr. Amanda Gillespie-Twardy, M.D
Dr. Amanda Gillespie-Twardy, M.D is a Hematology & Oncology healthcare provider based in Roanoke, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/22/2007. The National Provider Identifier (NPI) number assigned to this provider is 1417140559.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amanda Gillespie-Twardy, M.D has received a total of $15,362 in payments from pharmaceutical and medical device companies, with $3.49 received in 2024. These payments were reported across 11 transactions from 8 companies. The most common payment nature is "" ($15,211).
As a Medicare-enrolled provider, Gillespie-Twardy has provided services to 17,741 Medicare beneficiaries, totaling 602,815 services with total Medicare billing of $7.5M. Data is available for 4 years (2020–2023), covering 317 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Roanoke, VA
- Active Since 08/22/2007
- Last Updated 10/29/2014
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1417140559
Products in Payments
- Flexitouch Plus (Device) $72.90
- NERLYNX (Drug) $23.27
- LUMAKRAS (Drug) $15.11
- ADCETRIS (Biological) $12.29
- Cabometyx (Drug) $11.60
- IBRANCE (Drug) $3.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Roanoke
Mark Kochenderfer, Md, MD
Hematology & Oncology — Payments: $12,819
Hematology & Oncology $12,819
Dr. Padmaja Mallidi, M.d, M.D
Hematology & Oncology — Payments: $1,580
Hematology & Oncology $1,580
Dr. Harry Mccoy, M.d, M.D
Hematology & Oncology — Payments: $544.52
Hematology & Oncology $544.52
Mrs. Kirsten Hinson, Fnp-C, FNP-C
Hematology & Oncology — Payments: $421.40
Hematology & Oncology $421.40
Joshua Morales, Md, MD
Hematology & Oncology — Payments: $412.41
Hematology & Oncology $412.41
Dr. William Fintel, M.d, M.D
Hematology & Oncology — Payments: $388.95
Hematology & Oncology $388.95